The Glassware Washing Facility (a CCSG Core since 1976) is a Cancer Center managed resource which provides cleaning and sterilization of reusable laboratory glassware, instruments and equipment and provides sterilization of biohazardous tissue culture waste from Center research laboratories. Routine services are washing, material wrapping/preparation for sterilization, pipette plugging, accomodating individual investigators'customized washing and preparation needs, centralized autoclaving for media and liquids and biohazardous material. The facility is located in the Bunting-Blaustein Cancer Research Building (CRB I) and services are provided by glassware washers supervised by the Laboratory Facilities and Services Manager. Service logs are maintained and each investigator is charged for these services. The newly upgraded facility is equiped with three washers, three autoclaves, two dryers and other assorted support equipment. Currently three glassware washing staff members process glassware, media and waste. In January 2006, this facility will provide support for Cancer Research Building II (CRB II), which will double the number of research investigators to whom the Core provides services. The existing facility has been recently renovated and has added one washer, one autoclave and one dryer. Casework has been added to increase and improve the efficiency of the prep/plugging area. There will also be one additional autoclave in CRBII to handle autoclaving of biohazardous waste. Two additional staff member will be added to handle the increased volumes from CRB II.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Christenson, Eric S; Antonarakis, Emmanuel S (2018) PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 23:123-133
El-Diwany, Ramy; Soliman, Mary; Sugawara, Sho et al. (2018) CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Sci Adv 4:eaat0843
Kyker-Snowman, Kelly; Erlanger Avigdor, Bracha; Nasim, Mansoor et al. (2018) A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Breast Cancer Res Treat 170:425-430
Bharathy, Narendra; Berlow, Noah E; Wang, Eric et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11:
Ambinder, Richard F (2018) A viral protein kinase drug target for tumors? J Clin Invest 128:2197-2198
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118

Showing the most recent 10 out of 2393 publications